Imexpharm Pharmaceutical Joint Stock Company has been formally recognized at the CSA 2026 awards for the third consecutive year, securing its position within the Top 50 Sustainable Businesses in Vietnam. Executive leadership noted that ESG (Environmental, Social, and Governance) parameters do not operate as an independent roadmap but are directly institutionalized into core business operations, linking product quality, resource efficiency, and financial transparency with investor relations.
The documented financial performance metrics, ESG implementation parameters, and international strategic shareholder transitions feature:
-
Financial Performance and Advanced EU-GMP Manufacturing Capacity:
-
Fiscal Year 2025 Readouts: Imexpharm logged gross revenues of 2,914 billion VND, representing a 16% year-over-year expansion. Net revenue reached 2,441 billion VND, driving gross profit margins up to 41%, while the company’s aggregate tax contributions to the state budget expanded by 21.3% over the same period.
-
Infrastructure and R&D Capabilities: The enterprise commands the largest volume of EU-GMP compliant manufacturing infrastructure in Vietnam, operating 12 certified lines across three distinct factory clusters. In 2025, the firm launched 25 novel products and sustained a pipeline of nearly 200 research and development (R&D) projects covering complex formulations, including intravenous infusions and lyophilized powders for nebulization.
-
-
Quantifiable Results Across the Three ESG Pillars:
-
Environmental (E): Adherence to European production standards optimized waste mitigation and energy oversight. Imexpharm achieved a 17% packaging recycling rate and cut electricity consumption intensity by 5.5%. These energy-saving initiatives shaved off 42,600 kWh annually, generating a cost optimization value of 30.24 billion VND (a 78.3% surge compared to the prior year).
-
Governance (G): Average labor productivity across the organization grew by 14.9%. The company initiated its inaugural corporate governance audit using the ASEAN Corporate Governance Scorecard, modernized its dedicated Investor Relations (IR) web portal, and accelerated digital transformation by deploying the Base management system alongside the iHRP human resource platform.
-
Social (S): Internal promotions for mid-level management rose by 12.8%, average training hours for executive staff increased by 8%, and the average employee income expanded by 12.1% year-over-year. For public health advocacy, the firm delivered Continuing Medical Education (CME) courses to over 1,400 licensed physicians and engaged with more than 6,000 healthcare experts via scientific symposiums.
-
-
Strategic Shareholder Transition and Alliances with Livzon Group:
-
In May, Imexpharm experienced a structural shift in its equity architecture as China-based Livzon Pharmaceutical Group finalized a public tender offer to acquire 67.87% of the company’s charter capital, replacing South Korea’s SK Group as the definitive controlling shareholder.
-
Livzon stands as one of only 23 global pharmaceutical enterprises indexed within the S&P Global Sustainability Yearbook 2025, operating manufacturing lines validated by the U.S. FDA, European, and Japanese regulatory bodies. Its specialized subsidiary, Livzon Bio, focuses heavily on advanced biotherapies, including monoclonal antibodies and CAR-T cell therapies engineered for oncology and autoimmune pathologies. This capital synergy is projected to accelerate Imexpharm’s macroeconomic scaling and international market integration.
-
Source: https://vnexpress.net/imexpharm-tich-hop-esg-vao-van-hanh-kinh-doanh-5084496.html